RESUMEN
A novel series of pyrido[1,2- a]benzimidazoles bearing Mannich base side chains and their metabolites were synthesized and evaluated for in vitro antiplasmodium activity, microsomal metabolic stability, reactive metabolite (RM) formation, and in vivo antimalarial efficacy in a mouse model. Oral administration of one of the derivatives at 4 × 50 mg/kg reduced parasitemia by 95% in Plasmodium berghei-infected mice, with a mean survival period of 16 days post-treatment. The in vivo efficacy of these derivatives is likely a consequence of their active metabolites, two of which showed potent in vitro antiplasmodium activity against chloroquine-sensitive and multidrug-resistant Plasmodium falciparum ( P. falciparum) strains. Rapid metabolism was observed for all the analogues with <40% of parent compound remaining after 30 min of incubation in liver microsomes. RM trapping studies detected glutathione adducts only in derivatives bearing 4-aminophenol moiety, with fragmentation signatures showing that this conjugation occurred on the phenyl ring of the Mannich base side chain. As with amodiaquine (AQ), interchanging the positions of the 4-hydroxyl and Mannich base side group or substituting the 4-hydroxyl with fluorine appeared to block bioactivation of the AQ-like derivatives though at the expense of antiplasmodium activity, which was significantly lowered.
Asunto(s)
Antimaláricos/administración & dosificación , Antimaláricos/química , Bencimidazoles/administración & dosificación , Bencimidazoles/química , Malaria/tratamiento farmacológico , Bases de Mannich/química , Plasmodium falciparum/efectos de los fármacos , Animales , Antimaláricos/síntesis química , Antimaláricos/farmacocinética , Bencimidazoles/síntesis química , Bencimidazoles/farmacocinética , Evaluación Preclínica de Medicamentos , Humanos , Malaria/parasitología , Masculino , Ratones , Ratones Endogámicos BALB C , Plasmodium berghei , Plasmodium falciparum/fisiología , Relación Estructura-ActividadRESUMEN
Malaria is one of the most significant causes of childhood mortality, but disease control efforts are threatened by resistance of the Plasmodium parasite to current therapies. Continued progress in combating malaria requires development of new, easy to administer drug combinations with broad-ranging activity against all manifestations of the disease. DSM265, a triazolopyrimidine-based inhibitor of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH), is the first DHODH inhibitor to reach clinical development for treatment of malaria. We describe studies profiling the biological activity, pharmacological and pharmacokinetic properties, and safety of DSM265, which supported its advancement to human trials. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drug-resistant parasite isolates. Favorable pharmacokinetic properties of DSM265 are predicted to provide therapeutic concentrations for more than 8 days after a single oral dose in the range of 200 to 400 mg. DSM265 was well tolerated in repeat-dose and cardiovascular safety studies in mice and dogs, was not mutagenic, and was inactive against panels of human enzymes/receptors. The excellent safety profile, blood- and liver-stage activity, and predicted long half-life in humans position DSM265 as a new potential drug combination partner for either single-dose treatment or once-weekly chemoprevention. DSM265 has advantages over current treatment options that are dosed daily or are inactive against the parasite liver stage.
Asunto(s)
Antimaláricos/química , Inhibidores Enzimáticos/química , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/prevención & control , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/antagonistas & inhibidores , Pirimidinas/química , Triazoles/química , Administración Oral , Animales , Antimaláricos/farmacocinética , Área Bajo la Curva , Células CACO-2 , Cristalografía por Rayos X , Dihidroorotato Deshidrogenasa , Perros , Evaluación Preclínica de Medicamentos , Inhibidores Enzimáticos/farmacocinética , Haplorrinos , Humanos , Concentración 50 Inhibidora , Ratones , Ratones Endogámicos NOD , Ratones SCID , Datos de Secuencia Molecular , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/química , Plasmodium falciparum , Pirimidinas/farmacocinética , Conejos , Especificidad por Sustrato , Triazoles/farmacocinéticaRESUMEN
Several of the enzymes related to the folate cycle are well-known for their role as clinically validated antimalarial targets. Nevertheless for serine hydroxymethyltransferase (SHMT), one of the key enzymes of this cycle, efficient inhibitors have not been described so far. On the basis of plant SHMT inhibitors from an herbicide optimization program, highly potent inhibitors of Plasmodium falciparum (Pf) and Plasmodium vivax (Pv) SHMT with a pyrazolopyran core structure were identified. Cocrystal structures of potent inhibitors with PvSHMT were solved at 2.6 Å resolution. These ligands showed activity (IC50/EC50 values) in the nanomolar range against purified PfSHMT, blood-stage Pf, and liver-stage P. berghei (Pb) cells and a high selectivity when assayed against mammalian cell lines. Pharmacokinetic limitations are the most plausible explanation for lack of significant activity of the inhibitors in the in vivo Pb mouse malaria model.
Asunto(s)
Antimaláricos/química , Antimaláricos/farmacología , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Glicina Hidroximetiltransferasa/antagonistas & inhibidores , Plasmodium falciparum/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos , Administración Oral , Animales , Antimaláricos/administración & dosificación , Antimaláricos/farmacocinética , Técnicas de Química Sintética , Cristalografía por Rayos X , Evaluación Preclínica de Medicamentos/métodos , Resistencia a Medicamentos/efectos de los fármacos , Inhibidores Enzimáticos/síntesis química , Femenino , Glicina Hidroximetiltransferasa/química , Glicina Hidroximetiltransferasa/metabolismo , Células Hep G2/efectos de los fármacos , Humanos , Hígado/metabolismo , Hígado/parasitología , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/parasitología , Ratones Endogámicos , Ratones SCID , Microsomas Hepáticos/efectos de los fármacos , Organismos Modificados Genéticamente , Plasmodium berghei/efectos de los fármacos , Plasmodium berghei/patogenicidad , Plasmodium falciparum/enzimología , Plasmodium falciparum/patogenicidad , Plasmodium vivax/enzimología , Plasmodium vivax/patogenicidad , Pirazoles/química , RatasRESUMEN
BACKGROUND: Recent whole cell in vitro screening campaigns identified thousands of compounds that are active against asexual blood stages of Plasmodium falciparum at submicromolar concentrations. These hits have been made available to the public, providing many novel chemical starting points for anti-malarial drug discovery programmes. Knowing which of these hits are fast-acting compounds is of great interest. Firstly, a fast action will ensure rapid relief of symptoms for the patient. Secondly, by rapidly reducing the parasitaemia, this could minimize the occurrence of mutations leading to new drug resistance mechanisms.An in vitro assay that provides information about the speed of action of test compounds has been developed by researchers at GlaxoSmithKline (GSK) in Spain. This assay also provides an in vitro measure for the ratio between parasitaemia at the onset of drug treatment and after one intra-erythrocytic cycle (parasite reduction ratio, PRR). Both parameters are needed to determine in vitro killing rates of anti-malarial compounds. A drawback of the killing rate assay is that it takes a month to obtain first results. METHODS: The approach described in the present study is focused only on the speed of action of anti-malarials. This has the advantage that initial results can be achieved within 4-7 working days, which helps to distinguish between fast and slow-acting compounds relatively quickly. It is expected that this new assay can be used as a filter in the early drug discovery phase, which will reduce the number of compounds progressing to secondary, more time-consuming assays like the killing rate assay. RESULTS: The speed of action of a selection of seven anti-malarial compounds was measured with two independent experimental procedures using modifications of the standard [3H]hypoxanthine incorporation assay. Depending on the outcome of both assays, the tested compounds were classified as either fast or non-fast-acting. CONCLUSION: The results obtained for the anti-malarials chloroquine, artesunate, atovaquone, and pyrimethamine are consistent with previous observations, suggesting the methodology is a valid way to rapidly identify fast-acting anti-malarial compounds. Another advantage of the approach is its ability to discriminate between static or cidal compound effects.
Asunto(s)
Antimaláricos/farmacología , Plasmodium falciparum/efectos de los fármacos , Evaluación Preclínica de Medicamentos/métodos , Concentración 50 Inhibidora , Pruebas de Sensibilidad Parasitaria/métodos , Factores de TiempoRESUMEN
CONTEXT: The emergence and spread of Plasmodium falciparum-resistant parasites to nearly all available antimalarial drugs pose a threat to malaria control and necessitates the need to continue the search for new effective and affordable drugs. Ethnomedicine has been shown to be a potential source of antimalarial compounds or source of template for the synthesis of novel antimalarial molecules. OBJECTIVE: The antiplasmodial activity and toxicity assessment of 30 plant extracts from eight medicinal plants identified in Nigerian ethnomedicine for the treatment of febrile illnesses were evaluated. MATERIALS AND METHODS: In vitro antimalarial activity was evaluated using Plasmodium falciparum NF54 (sensitive to all antimalarial drugs) and K1 (chloroquine/pyrimethamine resistant) strains in the [(3)H]-hypoxanthine incorporation assay. Toxicity was determined against mammalian L6 cells using Alamar blue assay. RESULTS: The ethyl acetate extract of leaves of Ocimum gratissimum Linn. (Labiatae) and hexane extract of stem bark of Trema orientalis (L.) Blume (Ulmaceae) showed the highest antiplasmodial activity (IC(50) 1.8-1.93 µg/mL) against P. falciparum K1 strain but elicited low cytotoxicity (selective index >10). However, hexane, ethyl acetate or methanol extracts of leaves of Terminalia catappa Linn. (Combretaceae), Jatropha curcas Linn. (Euphorbiaceae), Vitex doniana Sweet. (Verbenaceae) and stem bark of Vitex doniana displayed antiplasmodial activity (IC(50) 2.3-16.9 µg/mL) with good selectivity (21-120) for malaria parasites. DISCUSSION AND CONCLUSION: The antiplasmodial activity of Terminalia catappa and Vitex doniana against P. falciparum K1 is being reported for the first time in Nigerian ethnomedicine and these plants could be potential source of antimalarial agents.
Asunto(s)
Antimaláricos/farmacología , Extractos Vegetales/farmacología , Plantas Medicinales/química , Plasmodium falciparum/efectos de los fármacos , Animales , Antimaláricos/aislamiento & purificación , Antimaláricos/toxicidad , Células Cultivadas , Etnofarmacología , Humanos , Concentración 50 Inhibidora , Medicinas Tradicionales Africanas , Mioblastos Esqueléticos/efectos de los fármacos , Mioblastos Esqueléticos/metabolismo , Nigeria , Fitoterapia/métodos , Extractos Vegetales/administración & dosificación , Extractos Vegetales/toxicidad , Ratas , Pruebas de ToxicidadRESUMEN
Three groups of compounds: (i) active peroxides (artemisinin and arterolene), (ii) inactive non-peroxidic derivatives (deoxyartemisinin and carbaOZ277) and (iii) inactive peroxide (OZ381) were tested by WEC system to provide insights into the relationship between chemical structure and embryotoxic potential, and to assess the relationship between embryotoxicity and antimalarial activity. Deoxyartemisinin, OZ381 and carbaOZ277 did not affect rat embryonic development. Artemisinin and arterolane affected primarily nucleated red blood cells (RBCs), inducing anemia and subsequent tissue damage in rat embryos, with NOELs for RBC damage at 0.1 and 0.175µg/mL, respectively. These data support the idea that only active antimalarial peroxides are able to interfere with normal embryonic development. In an attempt to establish whether and to what extent activity as antimalarials and embryotoxicity can be divorced, IC(50)s for activity in Plasmodium falciparum strains and the NOELs for RBCs were compared. From this comparison, arterolane showed a better safety margin than artemisinin.
Asunto(s)
Antimaláricos/toxicidad , Embrión de Mamíferos/efectos de los fármacos , Peróxidos/toxicidad , Teratógenos/toxicidad , Adamantano/análogos & derivados , Adamantano/toxicidad , Animales , Antimaláricos/química , Artemisininas/toxicidad , Región Branquial/efectos de los fármacos , Región Branquial/patología , Evaluación Preclínica de Medicamentos/métodos , Técnicas de Cultivo de Embriones , Embrión de Mamíferos/irrigación sanguínea , Embrión de Mamíferos/patología , Desarrollo Embrionario/efectos de los fármacos , Eritrocitos/efectos de los fármacos , Eritrocitos/patología , Compuestos Heterocíclicos con 1 Anillo/química , Compuestos Heterocíclicos con 1 Anillo/toxicidad , Concentración 50 Inhibidora , Nivel sin Efectos Adversos Observados , Peróxidos/química , Plasmodium falciparum/efectos de los fármacos , Ratas , Compuestos de Espiro/química , Compuestos de Espiro/toxicidad , Relación Estructura-Actividad , Teratógenos/química , Saco Vitelino/irrigación sanguínea , Saco Vitelino/efectos de los fármacos , Saco Vitelino/patologíaRESUMEN
Plasmodium falciparum, the causative agent of the most deadly form of human malaria, is unable to salvage pyrimidines and must rely on de novo biosynthesis for survival. Dihydroorotate dehydrogenase (DHODH) catalyzes the rate-limiting step in the pyrimidine biosynthetic pathway and represents a potential target for anti-malarial therapy. A high throughput screen and subsequent medicinal chemistry program identified a series of N-alkyl-5-(1H-benzimidazol-1-yl)thiophene-2-carboxamides with low nanomolar in vitro potency against DHODH from P. falciparum, P. vivax, and P. berghei. The compounds were selective for the parasite enzymes over human DHODH, and x-ray structural data on the analog Genz-667348, demonstrated that species selectivity could be attributed to amino acid differences in the inhibitor-binding site. Compounds from this series demonstrated in vitro potency against the 3D7 and Dd2 strains of P. falciparum, good tolerability and oral exposure in the mouse, and ED(50) values in the 4-day murine P. berghei efficacy model of 13-21 mg/kg/day with oral twice-daily dosing. In particular, treatment with Genz-667348 at 100 mg/kg/day resulted in sterile cure. Two recent analogs of Genz-667348 are currently undergoing pilot toxicity testing to determine suitability as clinical development candidates.
Asunto(s)
Antimaláricos/farmacología , Inhibidores Enzimáticos/farmacología , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/enzimología , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/antagonistas & inhibidores , Plasmodium falciparum/enzimología , Proteínas Protozoarias/antagonistas & inhibidores , Animales , Línea Celular , Dihidroorotato Deshidrogenasa , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Humanos , Imidazoles/farmacología , Ratones , Ratones Endogámicos NOD , Ratones SCID , Plasmodium berghei/enzimología , Plasmodium vivax/enzimología , RatasRESUMEN
Ancient Chinese herbal texts as far back as the 4th Century Zhou hou bei ji fang describe methods for the use of Qing Hao (Artemisia annua) for the treatment of intermittent fevers. Today, the A. annua constituent artemisinin is an important antimalarial drug and the herb itself is being grown and used locally for malaria treatment although this practice is controversial. Here we show that the ancient Chinese methods that involved either soaking, (followed by wringing) or pounding, (followed by squeezing) the fresh herb are more effective in producing artemisinin-rich extracts than the usual current method of preparing herbal teas from the dried herb. The concentrations of artemisinin in the extracts was up to 20-fold higher than that in a herbal tea prepared from the dried herb, but the amount of total artemisinin extracted by the Chinese methods was much less than that removed in the herbal tea. While both extracts exhibited potent in vitro activities against Plasmodium falciparum, only the pounded juice contained sufficient artemisinin to suppress parasitaemia in P. berghei infected mice. The implications of these results are discussed in the context of malaria treatment using A. annua infusions.
Asunto(s)
Antimaláricos/uso terapéutico , Artemisininas/aislamiento & purificación , Medicamentos Herbarios Chinos/aislamiento & purificación , Medicamentos Herbarios Chinos/uso terapéutico , Medicina Tradicional China/métodos , Administración Oral , Animales , Antimaláricos/administración & dosificación , Antimaláricos/farmacología , Medicamentos Herbarios Chinos/administración & dosificación , Medicamentos Herbarios Chinos/farmacología , Malaria/tratamiento farmacológico , Ratones , Plasmodium berghei/efectos de los fármacosRESUMEN
The standard method for in vitro antimalarial drug screening is based on the isotopic assay which is expensive and utilizes radioactive materials with limited availability, safety, and disposal problems in developing countries. The use of non-radioactive DNA stains SYBR Green I (SG) and PICO green (PG) for antimalarial screening had been reported. However, the use of the two DNA stains for antimalarial screening of medicinal plants has not been compared. Thus, this study compared SG, PG with the [(3)H]-hypoxanthine (HP) incorporation assays for in vitro antimalarial screening of medicinal plants. The 50% inhibitory concentration (IC(50)) values obtained using the three methods for antimalarial activity of medicinal plants and standard antimalarial drugs were similar. Data generated from this study suggests that the non-radioactive micro-flourimetric assay is sufficiently sensitive to reproducibly identify plant extracts with antimalarial activity from those lacking activity. The HP-based assay exhibited the most robust signal-to-noise ratio of 100, compared with signal-to-noise ratios of 7 for SG and 8 for PG. The SG-based assay is less expensive than the PG- and HP-based assays. SG appears to be a cost-effective alternative for antimalarial drug screening and a viable technique that may facilitate antimalarial drug discovery process especially in developing countries.
Asunto(s)
Antimaláricos/farmacología , Evaluación Preclínica de Medicamentos/métodos , Medicina Tradicional , Extractos Vegetales/farmacología , Plantas Medicinales/química , Plasmodium/efectos de los fármacos , Animales , Benzotiazoles , Supervivencia Celular/efectos de los fármacos , Diaminas , Humanos , Hipoxantina/metabolismo , Concentración 50 Inhibidora , Nigeria , Compuestos Orgánicos/metabolismo , Quinolinas , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Coloración y Etiquetado/métodos , Tritio/metabolismoRESUMEN
Scleria striatonux (Cyperaceae), a spice traditionally used in Cameroon, displayed an antiplasmodial activity. Two new sesquiterpenes, 1 (sclerienone A) and 2 (sclerienone B), have subsequently been isolated from the methylene chloride/methanol extract of the rhizome. Their separation involved a combination of methods including repeated silica gel open column chromatography, Sephadex LH-20 and semi-preparative HPLC. Structure elucidation was achieved by means of chemical tests and extensive spectral studies.
Asunto(s)
Cyperaceae/química , Sesquiterpenos/química , Animales , Estructura Molecular , Plasmodium/efectos de los fármacos , Rizoma/química , Sesquiterpenos/farmacologíaRESUMEN
Okundoperoxide (1) was isolated by bioassay-guided fractionation of extracts from Scleria striatinux (syn. S. striatonux). The compound contains a cyclic endoperoxide structural moiety and possesses moderate antimalarial activity.
Asunto(s)
Antimaláricos/aislamiento & purificación , Antimaláricos/farmacología , Cyperaceae/química , Plantas Medicinales/química , Sesquiterpenos/aislamiento & purificación , Sesquiterpenos/farmacología , Antimaláricos/química , Cloroquina/farmacología , Resistencia a Medicamentos/efectos de los fármacos , Estructura Molecular , Resonancia Magnética Nuclear Biomolecular , Raíces de Plantas/química , Plasmodium falciparum/efectos de los fármacos , Sesquiterpenos/química , EstereoisomerismoRESUMEN
The discovery of artemisinin more than 30 years ago provided a completely new antimalarial structural prototype; that is, a molecule with a pharmacophoric peroxide bond in a unique 1,2,4-trioxane heterocycle. Available evidence suggests that artemisinin and related peroxidic antimalarial drugs exert their parasiticidal activity subsequent to reductive activation by haem, released as a result of haemoglobin digestion by the malaria-causing parasite. This irreversible redox reaction produces carbon-centred free radicals, leading to alkylation of haem and proteins (enzymes), one of which--the sarcoplasmic-endoplasmic reticulum ATPase PfATP6 (ref. 7)--may be critical to parasite survival. Notably, there is no evidence of drug resistance to any member of the artemisinin family of drugs. The chemotherapy of malaria has benefited greatly from the semi-synthetic artemisinins artemether and artesunate as they rapidly reduce parasite burden, have good therapeutic indices and provide for successful treatment outcomes. However, as a drug class, the artemisinins suffer from chemical (semi-synthetic availability, purity and cost), biopharmaceutical (poor bioavailability and limiting pharmacokinetics) and treatment (non-compliance with long treatment regimens and recrudescence) issues that limit their therapeutic potential. Here we describe how a synthetic peroxide antimalarial drug development candidate was identified in a collaborative drug discovery project.